U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H20N4O
Molecular Weight 320.3883
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AG-14361

SMILES

CN(C)CC1=CC=C(C=C1)C2=NC3=C4N2CCNC(=O)C4=CC=C3

InChI

InChIKey=SEKJSSBJKFLZIT-UHFFFAOYSA-N
InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)

HIDE SMILES / InChI

Molecular Formula C19H20N4O
Molecular Weight 320.3883
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16322308

AG-14361 binds to the catalytic domain of PARP-1 and is a potent, selective inhibitor. AG-14361 is a selective inhibitor of PARP-1 with Ki50 value <5 nM. AG-14361 is the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
14.0 nM [IC50]
Conditions
PubMed

PubMed

TitleDatePubMed
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
2003 Jan 16
Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
2003 Sep 15
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
2004 Feb 1
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
2004 Jan 7
The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
2005 Dec 1
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
2010 Oct
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
2012 Nov 1
Patents

Sample Use Guides

50 mg/kg, intraperitoneally
Route of Administration: Intraperitoneal
AG-14361 (0.4 uM) potentiated IR in PARP-1(+/+) (PF(90) = 1.37 +/- 0.03) but not PARP-1(-/-) MEFs cells.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:00:07 GMT 2023
Edited
by admin
on Sat Dec 16 09:00:07 GMT 2023
Record UNII
48N0U0K50I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AG-14361
Common Name English
IMIDAZO(4,5,1-JK)(1,4)BENZODIAZEPIN-7(4H)-ONE, 2-(4-((DIMETHYLAMINO)METHYL)PHENYL)-5,6-DIHYDRO-
Systematic Name English
Code System Code Type Description
CAS
328543-09-5
Created by admin on Sat Dec 16 09:00:07 GMT 2023 , Edited by admin on Sat Dec 16 09:00:07 GMT 2023
PRIMARY
PUBCHEM
9840076
Created by admin on Sat Dec 16 09:00:07 GMT 2023 , Edited by admin on Sat Dec 16 09:00:07 GMT 2023
PRIMARY
FDA UNII
48N0U0K50I
Created by admin on Sat Dec 16 09:00:07 GMT 2023 , Edited by admin on Sat Dec 16 09:00:07 GMT 2023
PRIMARY
EPA CompTox
DTXSID80186513
Created by admin on Sat Dec 16 09:00:07 GMT 2023 , Edited by admin on Sat Dec 16 09:00:07 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY